GlassScriptPhysician profile
Kenneth A Kelsen
NPI 1538292321
$4,736.40
in general payments reported to CMS, 2019-2025
29 companies · $1,350 in 2025
The $1,350 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $539 · 2020: $142 · 2021: $381 · 2022: $562 · 2023: $628 · 2024: $1,135 · 2025: $1,350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,113.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,575.79 | 2019-2025 | Tremfya, Stelara, Remicade |
| Gilead Sciences, INC. | $853.29 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $452.94 | 2019-2025 | Entyvio |
| Madrigal Pharmaceuticals | $319.28 | 2024-2025 | Rezdiffra |
| Lilly USA, LLC | $201.98 | 2023-2025 | Omvoh |
| Janssen Pharmaceuticals, INC | $125.00 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $119.75 | 2024 | Voquezna |
| Glaxosmithkline, LLC. | $113.08 | 2021-2023 | Arexvy |
| Pfizer INC. | $99.58 | 2019-2024 | |
| Qol Medical, LLC | $97.99 | 2023-2025 | Sucraid, Sucraid |
| Boston Scientific Corporation | $91.22 | 2019-2023 | Watchman Flx |
| Janssen Scientific Affairs, LLC | $90.16 | 2023 | |
| Novartis Pharmaceuticals Corporation | $76.50 | 2022-2023 | |
| Genzyme Corporation | $56.48 | 2023 | |
| Pentax of America, INC. | $54.97 | 2024 | Pentax Medical, Inspira, C2 Cryoballoon Focal Controller |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $49.71 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $45.64 | 2022 | |
| Amgen INC. | $38.91 | 2019-2020 | |
| Celltrion USA INC. | $33.27 | 2025 | Vegzelma |
| Merck Sharp & Dohme LLC | $30.65 | 2022 | |
| Smith+Nephew, INC. | $29.10 | 2021 | |
| Shionogi INC | $28.37 | 2020 | |
| Novo Nordisk INC | $26.17 | 2025 | Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.54 | 2024 | Caplyta |
| Ipsen Biopharmaceuticals, INC | $23.15 | 2025 | Iqirvo |
| Braintree Laboratories, INC. | $22.17 | 2025 | Sutab, Suflave |
| Capsovision, INC. | $21.73 | 2025 | Capsocam Plus |
| Sunovion Pharmaceuticals INC. | $17.33 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Kelsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.